Effectiveness of the BBIBP-CorV vaccine in preventing infection and death in health care workers in Peru 2021
Descripción del Articulo
Background: During 2021, Peru started the vaccination against SARS-CoV-2 using the BBIBP-CorV inactivated virus vaccine for health care workers (HCW). We aim to evaluate the effectiveness of the BBIBP-CorV vaccine to prevent SARS-CoV-2 infection and deaths among HCWs. Methods: Retrospective cohort s...
Autores: | , , , , , , |
---|---|
Formato: | artículo |
Fecha de Publicación: | 2023 |
Institución: | Seguro Social de Salud |
Repositorio: | ESSALUD-Institucional |
Lenguaje: | inglés |
OAI Identifier: | oai:repositorio.essalud.gob.pe:20.500.12959/3472 |
Enlace del recurso: | https://hdl.handle.net/20.500.12959/3472 https://doi.org/10.1016/j.tmaid.2023.102565 |
Nivel de acceso: | acceso abierto |
Materia: | Effectiveness Health care workers BBIBP-CorV Covid-19 Infecciones por coronavirus Perú https://purl.org/pe-repo/ocde/ford#3.03.08 https://purl.org/pe-repo/ocde/ford#3.03.09 |
id |
ESSA_e89854b15c8c6dc5d460dd3b89c53097 |
---|---|
oai_identifier_str |
oai:repositorio.essalud.gob.pe:20.500.12959/3472 |
network_acronym_str |
ESSA |
network_name_str |
ESSALUD-Institucional |
repository_id_str |
4277 |
dc.title.es_PE.fl_str_mv |
Effectiveness of the BBIBP-CorV vaccine in preventing infection and death in health care workers in Peru 2021 |
dc.title.alternative.es_PE.fl_str_mv |
Efectividad de la vacuna BBIBP-CorV en la prevención de infección y muerte en trabajadores de la salud en Perú 2021 |
title |
Effectiveness of the BBIBP-CorV vaccine in preventing infection and death in health care workers in Peru 2021 |
spellingShingle |
Effectiveness of the BBIBP-CorV vaccine in preventing infection and death in health care workers in Peru 2021 Silva-Valencia, Javier Effectiveness Health care workers BBIBP-CorV Covid-19 Infecciones por coronavirus Perú https://purl.org/pe-repo/ocde/ford#3.03.08 https://purl.org/pe-repo/ocde/ford#3.03.09 |
title_short |
Effectiveness of the BBIBP-CorV vaccine in preventing infection and death in health care workers in Peru 2021 |
title_full |
Effectiveness of the BBIBP-CorV vaccine in preventing infection and death in health care workers in Peru 2021 |
title_fullStr |
Effectiveness of the BBIBP-CorV vaccine in preventing infection and death in health care workers in Peru 2021 |
title_full_unstemmed |
Effectiveness of the BBIBP-CorV vaccine in preventing infection and death in health care workers in Peru 2021 |
title_sort |
Effectiveness of the BBIBP-CorV vaccine in preventing infection and death in health care workers in Peru 2021 |
author |
Silva-Valencia, Javier |
author_facet |
Silva-Valencia, Javier Soto-Becerra, Percy Escobar Agreda, Stefan Fernández Navarro, Manuel Moscoso Porras, Miguel Solari, Lely Mayta Tristán, Percy |
author_role |
author |
author2 |
Soto-Becerra, Percy Escobar Agreda, Stefan Fernández Navarro, Manuel Moscoso Porras, Miguel Solari, Lely Mayta Tristán, Percy |
author2_role |
author author author author author author |
dc.contributor.author.fl_str_mv |
Silva-Valencia, Javier Soto-Becerra, Percy Escobar Agreda, Stefan Fernández Navarro, Manuel Moscoso Porras, Miguel Solari, Lely Mayta Tristán, Percy |
dc.subject.es_PE.fl_str_mv |
Effectiveness Health care workers BBIBP-CorV Covid-19 Infecciones por coronavirus Perú |
topic |
Effectiveness Health care workers BBIBP-CorV Covid-19 Infecciones por coronavirus Perú https://purl.org/pe-repo/ocde/ford#3.03.08 https://purl.org/pe-repo/ocde/ford#3.03.09 |
dc.subject.ocde.es_PE.fl_str_mv |
https://purl.org/pe-repo/ocde/ford#3.03.08 https://purl.org/pe-repo/ocde/ford#3.03.09 |
description |
Background: During 2021, Peru started the vaccination against SARS-CoV-2 using the BBIBP-CorV inactivated virus vaccine for health care workers (HCW). We aim to evaluate the effectiveness of the BBIBP-CorV vaccine to prevent SARS-CoV-2 infection and deaths among HCWs. Methods: Retrospective cohort study, from February 9 to June 30, 2021, using national registries of health care workers, laboratory tests for SARS-CoV-2 and deaths. We calculated the vaccine effectiveness for preventing laboratory-confirmed SARS-CoV-2 infection, COVID-19-mortality, and all-cause mortality among partially immunized and fully immunized HCWs. An extension of Cox proportional hazards regression was used to model the mortality results, and Poisson regression was used to model SARS-CoV-2 infection. Results: The study included 606,772 eligible HCWs, the mean age was 40 (IQR: 33.0, 51.0). In fully immunized HCW, the effectiveness for preventing all-cause mortality was 83.6 (95% CI: 80.2 to 86.4), 88.7 (95% CI: 85.1 to 91.4) for preventing COVID-19 mortality, and 40.3 (95% CI 38.9 to 41.6) for preventing SARS-CoV-2 infection. Conclusion: The BBIBP-CorV vaccine showed high levels of effectiveness for preventing all-cause and COVID-19 deaths among fully immunized HCW. These results were consistent within different subgroups and sensitivity analyses. However, the effectiveness for preventing infection was suboptimal in this particular setting. |
publishDate |
2023 |
dc.date.accessioned.none.fl_str_mv |
2023-03-17T18:11:46Z |
dc.date.available.none.fl_str_mv |
2023-03-17T18:11:46Z |
dc.date.issued.fl_str_mv |
2023-03-16 |
dc.type.es_PE.fl_str_mv |
info:eu-repo/semantics/article |
format |
article |
dc.identifier.citation.es_PE.fl_str_mv |
Travel Medicine and Infectious Disease. 2023 |
dc.identifier.uri.none.fl_str_mv |
https://hdl.handle.net/20.500.12959/3472 |
dc.identifier.doi.none.fl_str_mv |
https://doi.org/10.1016/j.tmaid.2023.102565 |
identifier_str_mv |
Travel Medicine and Infectious Disease. 2023 |
url |
https://hdl.handle.net/20.500.12959/3472 https://doi.org/10.1016/j.tmaid.2023.102565 |
dc.language.iso.es_PE.fl_str_mv |
eng |
language |
eng |
dc.relation.uri.es_PE.fl_str_mv |
https://www.sciencedirect.com/science/article/pii/S147789392300025X?via%3Dihub |
dc.rights.es_PE.fl_str_mv |
info:eu-repo/semantics/openAccess |
dc.rights.uri.es_PE.fl_str_mv |
https://creativecommons.org/licenses/by-nc-sa/4.0/ |
eu_rights_str_mv |
openAccess |
rights_invalid_str_mv |
https://creativecommons.org/licenses/by-nc-sa/4.0/ |
dc.format.es_PE.fl_str_mv |
application/pdf |
dc.publisher.es_PE.fl_str_mv |
Royal College of Physicians and Surgeons de Glasgow |
dc.source.none.fl_str_mv |
reponame:ESSALUD-Institucional instname:Seguro Social de Salud instacron:ESSALUD |
instname_str |
Seguro Social de Salud |
instacron_str |
ESSALUD |
institution |
ESSALUD |
reponame_str |
ESSALUD-Institucional |
collection |
ESSALUD-Institucional |
bitstream.url.fl_str_mv |
https://repositorio.essalud.gob.pe/bitstream/20.500.12959/3472/1/Effectiveness%20of%20the%20BBIBP-CorV%20vaccine.pdf https://repositorio.essalud.gob.pe/bitstream/20.500.12959/3472/2/license.txt https://repositorio.essalud.gob.pe/bitstream/20.500.12959/3472/3/Effectiveness%20of%20the%20BBIBP-CorV%20vaccine.pdf.txt https://repositorio.essalud.gob.pe/bitstream/20.500.12959/3472/4/Effectiveness%20of%20the%20BBIBP-CorV%20vaccine.pdf.jpg |
bitstream.checksum.fl_str_mv |
e10ded056ba9a393f621f4f582e3dbd6 8a4605be74aa9ea9d79846c1fba20a33 6cae03fd417e037de4c69bcdf8a533da 98800c9164ab41f482c4a6348ec2f6b8 |
bitstream.checksumAlgorithm.fl_str_mv |
MD5 MD5 MD5 MD5 |
repository.name.fl_str_mv |
Repositorio Seguro Social de Salud – ESSALUD |
repository.mail.fl_str_mv |
bibliotecacentral@essalud.gob.pe |
_version_ |
1813537148405547008 |
spelling |
Silva-Valencia, JavierSoto-Becerra, PercyEscobar Agreda, StefanFernández Navarro, ManuelMoscoso Porras, MiguelSolari, LelyMayta Tristán, Percy2023-03-17T18:11:46Z2023-03-17T18:11:46Z2023-03-16Travel Medicine and Infectious Disease. 2023https://hdl.handle.net/20.500.12959/3472https://doi.org/10.1016/j.tmaid.2023.102565Background: During 2021, Peru started the vaccination against SARS-CoV-2 using the BBIBP-CorV inactivated virus vaccine for health care workers (HCW). We aim to evaluate the effectiveness of the BBIBP-CorV vaccine to prevent SARS-CoV-2 infection and deaths among HCWs. Methods: Retrospective cohort study, from February 9 to June 30, 2021, using national registries of health care workers, laboratory tests for SARS-CoV-2 and deaths. We calculated the vaccine effectiveness for preventing laboratory-confirmed SARS-CoV-2 infection, COVID-19-mortality, and all-cause mortality among partially immunized and fully immunized HCWs. An extension of Cox proportional hazards regression was used to model the mortality results, and Poisson regression was used to model SARS-CoV-2 infection. Results: The study included 606,772 eligible HCWs, the mean age was 40 (IQR: 33.0, 51.0). In fully immunized HCW, the effectiveness for preventing all-cause mortality was 83.6 (95% CI: 80.2 to 86.4), 88.7 (95% CI: 85.1 to 91.4) for preventing COVID-19 mortality, and 40.3 (95% CI 38.9 to 41.6) for preventing SARS-CoV-2 infection. Conclusion: The BBIBP-CorV vaccine showed high levels of effectiveness for preventing all-cause and COVID-19 deaths among fully immunized HCW. These results were consistent within different subgroups and sensitivity analyses. However, the effectiveness for preventing infection was suboptimal in this particular setting.Antescedentes: Durante 2021, Perú inició la vacunación contra el SARS-CoV-2 utilizando la vacuna de virus inactivado BBIBP-CorV para trabajadores de la salud (TS). Nuestro objetivo es evaluar la eficacia de la vacuna BBIBP-CorV para prevenir la infección por SARS-CoV-2 y las muertes entre los trabajadores sanitarios. Métodos: Estudio de cohorte retrospectivo, del 9 de febrero al 30 de junio de 2021, utilizando registros nacionales de trabajadores de la salud, pruebas de laboratorio para SARS-CoV-2 y defunciones. Calculamos la efectividad de la vacuna para prevenir la infección por SARS-CoV-2 confirmada por laboratorio, la mortalidad por COVID-19 y la mortalidad por todas las causas entre los trabajadores de la salud parcialmente inmunizados y totalmente inmunizados. Se usó una extensión de la regresión de riesgos proporcionales de Cox para modelar los resultados de mortalidad, y se usó la regresión de Poisson para modelar la infección por SARS-CoV-2. Resultados: El estudio incluyó a 606 772 HCW elegibles, la edad media fue de 40 años (IQR: 33,0, 51,0). En trabajadores de la salud totalmente inmunizados, la eficacia para prevenir la mortalidad por todas las causas fue de 83,6 (IC del 95 %: 80,2 a 86,4), 88,7 (IC del 95 %: 85,1 a 91,4) para prevenir la mortalidad por COVID-19 y 40,3 (IC del 95 %: 38,9 a 91,4). 41.6) para prevenir la infección por SARS-CoV-2. Conclusión: La vacuna BBIBP-CorV mostró altos niveles de efectividad para prevenir muertes por todas las causas y por COVID-19 entre trabajadores de la salud completamente inmunizados. Estos resultados fueron consistentes dentro de diferentes subgrupos y análisis de sensibilidad. Sin embargo, la efectividad para prevenir infecciones fue subóptima en este entorno particular.application/pdfengRoyal College of Physicians and Surgeons de Glasgowhttps://www.sciencedirect.com/science/article/pii/S147789392300025X?via%3Dihubinfo:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/4.0/EffectivenessHealth care workersBBIBP-CorVCovid-19Infecciones por coronavirusPerúhttps://purl.org/pe-repo/ocde/ford#3.03.08https://purl.org/pe-repo/ocde/ford#3.03.09Effectiveness of the BBIBP-CorV vaccine in preventing infection and death in health care workers in Peru 2021Efectividad de la vacuna BBIBP-CorV en la prevención de infección y muerte en trabajadores de la salud en Perú 2021info:eu-repo/semantics/articlereponame:ESSALUD-Institucionalinstname:Seguro Social de Saludinstacron:ESSALUDORIGINALEffectiveness of the BBIBP-CorV vaccine.pdfEffectiveness of the BBIBP-CorV vaccine.pdfapplication/pdf1462433https://repositorio.essalud.gob.pe/bitstream/20.500.12959/3472/1/Effectiveness%20of%20the%20BBIBP-CorV%20vaccine.pdfe10ded056ba9a393f621f4f582e3dbd6MD51LICENSElicense.txtlicense.txttext/plain; charset=utf-81748https://repositorio.essalud.gob.pe/bitstream/20.500.12959/3472/2/license.txt8a4605be74aa9ea9d79846c1fba20a33MD52TEXTEffectiveness of the BBIBP-CorV vaccine.pdf.txtEffectiveness of the BBIBP-CorV vaccine.pdf.txtExtracted texttext/plain46921https://repositorio.essalud.gob.pe/bitstream/20.500.12959/3472/3/Effectiveness%20of%20the%20BBIBP-CorV%20vaccine.pdf.txt6cae03fd417e037de4c69bcdf8a533daMD53THUMBNAILEffectiveness of the BBIBP-CorV vaccine.pdf.jpgEffectiveness of the BBIBP-CorV vaccine.pdf.jpgGenerated Thumbnailimage/jpeg4805https://repositorio.essalud.gob.pe/bitstream/20.500.12959/3472/4/Effectiveness%20of%20the%20BBIBP-CorV%20vaccine.pdf.jpg98800c9164ab41f482c4a6348ec2f6b8MD5420.500.12959/3472oai:repositorio.essalud.gob.pe:20.500.12959/34722023-03-18 03:00:26.649Repositorio Seguro Social de Salud – ESSALUDbibliotecacentral@essalud.gob.peTk9URTogUExBQ0UgWU9VUiBPV04gTElDRU5TRSBIRVJFClRoaXMgc2FtcGxlIGxpY2Vuc2UgaXMgcHJvdmlkZWQgZm9yIGluZm9ybWF0aW9uYWwgcHVycG9zZXMgb25seS4KCk5PTi1FWENMVVNJVkUgRElTVFJJQlVUSU9OIExJQ0VOU0UKCkJ5IHNpZ25pbmcgYW5kIHN1Ym1pdHRpbmcgdGhpcyBsaWNlbnNlLCB5b3UgKHRoZSBhdXRob3Iocykgb3IgY29weXJpZ2h0Cm93bmVyKSBncmFudHMgdG8gRFNwYWNlIFVuaXZlcnNpdHkgKERTVSkgdGhlIG5vbi1leGNsdXNpdmUgcmlnaHQgdG8gcmVwcm9kdWNlLAp0cmFuc2xhdGUgKGFzIGRlZmluZWQgYmVsb3cpLCBhbmQvb3IgZGlzdHJpYnV0ZSB5b3VyIHN1Ym1pc3Npb24gKGluY2x1ZGluZwp0aGUgYWJzdHJhY3QpIHdvcmxkd2lkZSBpbiBwcmludCBhbmQgZWxlY3Ryb25pYyBmb3JtYXQgYW5kIGluIGFueSBtZWRpdW0sCmluY2x1ZGluZyBidXQgbm90IGxpbWl0ZWQgdG8gYXVkaW8gb3IgdmlkZW8uCgpZb3UgYWdyZWUgdGhhdCBEU1UgbWF5LCB3aXRob3V0IGNoYW5naW5nIHRoZSBjb250ZW50LCB0cmFuc2xhdGUgdGhlCnN1Ym1pc3Npb24gdG8gYW55IG1lZGl1bSBvciBmb3JtYXQgZm9yIHRoZSBwdXJwb3NlIG9mIHByZXNlcnZhdGlvbi4KCllvdSBhbHNvIGFncmVlIHRoYXQgRFNVIG1heSBrZWVwIG1vcmUgdGhhbiBvbmUgY29weSBvZiB0aGlzIHN1Ym1pc3Npb24gZm9yCnB1cnBvc2VzIG9mIHNlY3VyaXR5LCBiYWNrLXVwIGFuZCBwcmVzZXJ2YXRpb24uCgpZb3UgcmVwcmVzZW50IHRoYXQgdGhlIHN1Ym1pc3Npb24gaXMgeW91ciBvcmlnaW5hbCB3b3JrLCBhbmQgdGhhdCB5b3UgaGF2ZQp0aGUgcmlnaHQgdG8gZ3JhbnQgdGhlIHJpZ2h0cyBjb250YWluZWQgaW4gdGhpcyBsaWNlbnNlLiBZb3UgYWxzbyByZXByZXNlbnQKdGhhdCB5b3VyIHN1Ym1pc3Npb24gZG9lcyBub3QsIHRvIHRoZSBiZXN0IG9mIHlvdXIga25vd2xlZGdlLCBpbmZyaW5nZSB1cG9uCmFueW9uZSdzIGNvcHlyaWdodC4KCklmIHRoZSBzdWJtaXNzaW9uIGNvbnRhaW5zIG1hdGVyaWFsIGZvciB3aGljaCB5b3UgZG8gbm90IGhvbGQgY29weXJpZ2h0LAp5b3UgcmVwcmVzZW50IHRoYXQgeW91IGhhdmUgb2J0YWluZWQgdGhlIHVucmVzdHJpY3RlZCBwZXJtaXNzaW9uIG9mIHRoZQpjb3B5cmlnaHQgb3duZXIgdG8gZ3JhbnQgRFNVIHRoZSByaWdodHMgcmVxdWlyZWQgYnkgdGhpcyBsaWNlbnNlLCBhbmQgdGhhdApzdWNoIHRoaXJkLXBhcnR5IG93bmVkIG1hdGVyaWFsIGlzIGNsZWFybHkgaWRlbnRpZmllZCBhbmQgYWNrbm93bGVkZ2VkCndpdGhpbiB0aGUgdGV4dCBvciBjb250ZW50IG9mIHRoZSBzdWJtaXNzaW9uLgoKSUYgVEhFIFNVQk1JU1NJT04gSVMgQkFTRUQgVVBPTiBXT1JLIFRIQVQgSEFTIEJFRU4gU1BPTlNPUkVEIE9SIFNVUFBPUlRFRApCWSBBTiBBR0VOQ1kgT1IgT1JHQU5JWkFUSU9OIE9USEVSIFRIQU4gRFNVLCBZT1UgUkVQUkVTRU5UIFRIQVQgWU9VIEhBVkUKRlVMRklMTEVEIEFOWSBSSUdIVCBPRiBSRVZJRVcgT1IgT1RIRVIgT0JMSUdBVElPTlMgUkVRVUlSRUQgQlkgU1VDSApDT05UUkFDVCBPUiBBR1JFRU1FTlQuCgpEU1Ugd2lsbCBjbGVhcmx5IGlkZW50aWZ5IHlvdXIgbmFtZShzKSBhcyB0aGUgYXV0aG9yKHMpIG9yIG93bmVyKHMpIG9mIHRoZQpzdWJtaXNzaW9uLCBhbmQgd2lsbCBub3QgbWFrZSBhbnkgYWx0ZXJhdGlvbiwgb3RoZXIgdGhhbiBhcyBhbGxvd2VkIGJ5IHRoaXMKbGljZW5zZSwgdG8geW91ciBzdWJtaXNzaW9uLgo= |
score |
13.909792 |
Nota importante:
La información contenida en este registro es de entera responsabilidad de la institución que gestiona el repositorio institucional donde esta contenido este documento o set de datos. El CONCYTEC no se hace responsable por los contenidos (publicaciones y/o datos) accesibles a través del Repositorio Nacional Digital de Ciencia, Tecnología e Innovación de Acceso Abierto (ALICIA).
La información contenida en este registro es de entera responsabilidad de la institución que gestiona el repositorio institucional donde esta contenido este documento o set de datos. El CONCYTEC no se hace responsable por los contenidos (publicaciones y/o datos) accesibles a través del Repositorio Nacional Digital de Ciencia, Tecnología e Innovación de Acceso Abierto (ALICIA).